Clinically isolated syndromes (CIS): treatment
Evidence-based neurology checklist on clinically isolated syndromes (cis): treatment: Acute treatment Methylprednisolone for acute attacks Disease modifying treatments (DMTs): use in CIS Disease modifying treatments (DMTs): agents
Acute treatment
- Methylprednisolone for acute attacks
Disease modifying treatments (DMTs): use in CIS
Disease modifying treatments (DMTs): agents
References
- Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012; 11:157-169.
- Marcus JF, Waubant EL. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist 2013; 3:65-80.
- Cobo-Calvo A, Tur C, Otero-Romero S, et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology 2023 (Online ahead of print).
- Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14:17562864211039648.
- García Merino A, Ramón Ara Callizo J, Fernández Fernández O, et al. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia 2017; 32:113-119.
- And 5 more. Subscribe to see the full list
